KSI-301-话题@MedSci

#KSI-301#

4篇内容 | 705人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1515304, encodeId=387b15153045f, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=湿性AMD药物KSI-301在临床试验中并不优于Eylea (aflibercept), objectType=article, longId=299741, objectId=beb8299e4190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beb8299e4190, replyNumber=0, likeNumber=43, createdTime=2022-03-01, rootId=0, userName=12498aa2m65(暂无昵称), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beb8299e4190, moduleTitle=湿性AMD药物KSI-301在临床试验中并不优于Eylea (aflibercept), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beb8299e4190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515303, encodeId=933715153030d, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=KSI-301治疗湿性AMD、糖尿病性黄斑水肿和视网膜静脉阻塞的Ib期临床试验取得积极结果, objectType=article, longId=187876, objectId=f10618e87660, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f10618e87660, replyNumber=0, likeNumber=36, createdTime=2020-02-13, rootId=0, userName=12498aa2m65(暂无昵称), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f10618e87660, moduleTitle=KSI-301治疗湿性AMD、糖尿病性黄斑水肿和视网膜静脉阻塞的Ib期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f10618e87660)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515302, encodeId=01a91515302b0, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=2019年视网膜协会年会：抗体生物聚合物共轭物（ABC）KSI-301治疗湿性AMD, objectType=article, longId=179538, objectId=2f8c1e95381c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f8c1e95381c, replyNumber=0, likeNumber=45, createdTime=2019-09-18, rootId=0, userName=12498aa2m65(暂无昵称), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f8c1e95381c, moduleTitle=2019年视网膜协会年会：抗体生物聚合物共轭物（ABC）KSI-301治疗湿性AMD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f8c1e95381c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果, objectType=article, longId=176439, objectId=b2ea1e643956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ea1e643956, replyNumber=0, likeNumber=41, createdTime=2019-07-31, rootId=0, userName=12498aa2m65(暂无昵称), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ea1e643956, moduleTitle=新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ea1e643956)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KSI-301

2020-05-29

12498aa2m65(暂无昵称) (审核中...)

前往app查看评论内容

#KSI-301#

湿性AMD药物KSI-301在临床试验中并不优于Eylea (aflibercept)

2022-03-01

12498aa2m65(暂无昵称) (审核中...)

前往app查看评论内容

#KSI-301#

KSI-301治疗湿性AMD、糖尿病性黄斑水肿和视网膜静脉阻塞的Ib期临床试验取得积极结果

2020-02-13

12498aa2m65(暂无昵称) (审核中...)

前往app查看评论内容

#KSI-301#

2019年视网膜协会年会：抗体生物聚合物共轭物（ABC）KSI-301治疗湿性AMD

2019-09-18

12498aa2m65(暂无昵称) (审核中...)

前往app查看评论内容

#KSI-301#

新型抗VEGF抗体聚合物KSI-301治疗湿性AMD、DME、RVO取得阶段成果

2019-07-31

科室
- - 订阅+
  - 更多科室
工具
服务